TD Asset Management Inc Has $1.23 Million Stake in Pharvaris N.V. (NASDAQ:PHVS)

TD Asset Management Inc raised its holdings in Pharvaris N.V. (NASDAQ:PHVS - Free Report) by 41.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 78,122 shares of the company's stock after buying an additional 22,906 shares during the quarter. TD Asset Management Inc owned 0.15% of Pharvaris worth $1,227,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC lifted its position in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares during the period. Soleus Capital Management L.P. lifted its holdings in Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after buying an additional 216,483 shares in the last quarter. Octagon Capital Advisors LP increased its position in Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after purchasing an additional 157,530 shares during the period. Rock Springs Capital Management LP lifted its holdings in Pharvaris by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock valued at $14,859,000 after buying an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock valued at $8,510,000 after purchasing an additional 118,408 shares during the period.

Pharvaris Trading Down 1.0%

PHVS traded down $0.22 during trading on Thursday, reaching $21.01. 28,246 shares of the company's stock were exchanged, compared to its average volume of 77,482. The firm has a fifty day moving average price of $19.06 and a two-hundred day moving average price of $17.11. The stock has a market capitalization of $1.10 billion, a PE ratio of -6.96 and a beta of -2.81. Pharvaris N.V. has a one year low of $11.51 and a one year high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Sell-side analysts expect that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PHVS shares. Cantor Fitzgerald reduced their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Finally, Guggenheim started coverage on shares of Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pharvaris has a consensus rating of "Buy" and a consensus target price of $36.20.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.